More on CRVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $16.06 |
|
|||
| Open | $15.94 | ||||
| 52 Wk High | $17.77 | ||||
| 52 Wk Low | $9.63 | ||||
| Day High | $16.14 | ||||
| Day Low | $15.38 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,403,191 | ||||
- Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
- Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: MILLER RICHARD A MD
- Form SCHEDULE 13D/A Corvus Pharmaceuticals, Filed by: ADAMS STREET PARTNERS LLC
- Form 4 Corvus Pharmaceuticals, For: Jan 28 Filed by: Thompson Peter A.
- Form SCHEDULE 13G Corvus Pharmaceuticals, Filed by: VANGUARD GROUP INC
- Corvus Pharmaceuticals (CRVS) PT Raised to $30 at Mizuho
- Form SCHEDULE 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
- Corvus Pharmaceuticals closes $201 million stock offering
- Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approxim
Entities mentioned with CRVS
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Jefferies & Co | View Related Stories »
- OrbiMed Advisors | View Related Stories »
- Show More...
